Lipid Nanoparticle-Mediated Vascular-Disrupting Therapy for Lung Metastasis

Abstract

Drug therapies targeting vasculature in metastatic cancer have not been highly effective and are therefore currently limited to an adjunctive role, such as in combination regimens. The development of novel, more effective therapeutic strategies with new mechanisms of action is therefore greatly needed. In a previous study, we reported a lipid nanoparticle (LNP)-based vascular-disrupting strategy utilizing cyclic RGD peptide-modified LNPs encapsulating small interfering RNA against Fas ligand (cRGD-LNP/siFasL). We combined this strategy for selective targeting of tumor endothelial cells with stimulator of interferon genes (STING) agonist-loaded LNPs (STING-LNPs). Here, we have demonstrated the potential of such combination therapy in treating lung metastases. We found that cRGD-LNPs accumulated in the vasculature within tumor colonies in the lung. A combination of cRGD-LNP/siFasL and STING-LNP induced significant antitumor effects in mouse models of Renca and 4T1 lung metastases. Moreover, this combination therapy reduced the vasculature within tumor colonies, with no obvious change in the surrounding normal lung tissue, indicating preferential vascular disruption. These findings demonstrate that the combination therapy exerts antitumor activity against lung metastases through tumor vascular disruption, indicating that such treatment is potentially a potent disrupter of the vascularity in metastatic tumors.

A Balanced Chromosomal Rearrangement Disrupting the Telomerase RNA Component Gene Causes Short Telomere-Mediated Pulmonary Fibrosis
Noa Hourvitz, Monica Neustadter-Blackman, Avraham Unterman +9
International journal of molecular sciences28 Sep 2026Peer-reviewedCC BYFull textGeneral biochemistryEurope PMC
The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis
Qun Miao, Rong Chen, Dong-mei Zhang +2
Acta Pharmacologica Sinica19 May 2026Peer-reviewedLicence not statedFull text1 citedMolecular biology & gene regulationPMC
Iron oxide nanoparticle-mediated elicitation enhances secondary metabolite production, antioxidant activity, and gene expression in Melia azedarach L
Vahid Rabbani, Ghasem-Ali Garoosi, Raheem Haddad +2
Scientific Reports16 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationCrossref
Lipid nanoparticle-mediated RNAi targeting of KRAS mutants sensitises colorectal cancer cells to chemotherapy
Y. Wang, S. Su, K. Zahra +4
bioRxiv15 Oct 2026PreprintCC BY-NC-NDFull textMolecular biology & gene regulationbioRxiv
Lipid nanoparticle-mediated transcription factor EB mRNA delivery for the treatment of metabolic dysfunction-associated steatotic liver disease.
Wenhao Ju, Chi Zhang, Tingting Zhang +9
Molecular biomedicine21 Oct 2026Peer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCDOAJ

Cite

BibTeX RIS

BibTeX

@article{ueda2026lipid,
  title = {{Lipid Nanoparticle-Mediated Vascular-Disrupting Therapy for Lung Metastasis}},
  author = {Tomoki Ueda and Rikito Endo and Yusuke Sato and Hideyoshi Harashima and Yuma Yamada and Takashi Nakamura},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2026},
  month = oct,
  doi = {10.1248/bpb.b26-00306},
  url = {https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00306/_article},
  note = {CC BY-NC},
}

RIS

TY  - JOUR
TI  - Lipid Nanoparticle-Mediated Vascular-Disrupting Therapy for Lung Metastasis
AU  - Tomoki Ueda
AU  - Rikito Endo
AU  - Yusuke Sato
AU  - Hideyoshi Harashima
AU  - Yuma Yamada
AU  - Takashi Nakamura
PY  - 2026
DA  - 2026/10/02
JO  - Biological and Pharmaceutical Bulletin
DO  - 10.1248/bpb.b26-00306
UR  - https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00306/_article
AB  - Drug therapies targeting vasculature in metastatic cancer have not been highly effective and are therefore currently limited to an adjunctive role, such as in combination regimens. The development of novel, more effective therapeutic strategies with new mechanisms of action is therefore greatly needed. In a previous study, we reported a lipid nanoparticle (LNP)-based vascular-disrupting strategy utilizing cyclic RGD peptide-modified LNPs encapsulating small interfering RNA against Fas ligand (cRGD-LNP/siFasL). We combined this strategy for selective targeting of tumor endothelial cells with stimulator of interferon genes (STING) agonist-loaded LNPs (STING-LNPs). Here, we have demonstrated the potential of such combination therapy in treating lung metastases. We found that cRGD-LNPs accumulated in the vasculature within tumor colonies in the lung. A combination of cRGD-LNP/siFasL and STING-LNP induced significant antitumor effects in mouse models of Renca and 4T1 lung metastases. Moreover, this combination therapy reduced the vasculature within tumor colonies, with no obvious change in the surrounding normal lung tissue, indicating preferential vascular disruption. These findings demonstrate that the combination therapy exerts antitumor activity against lung metastases through tumor vascular disruption, indicating that such treatment is potentially a potent disrupter of the vascularity in metastatic tumors.
SN  - 1347-5215
SN  - 0918-6158
ER  -

Abstract

Related

Cite